UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Kinase Fusion Gene:PIM2_STOML2 |
Kinase Fusion Protein Summary |
Kinase Fusion gene summary |
Kinase Fusion partner gene information | Kinase Fusion gene name: PIM2_STOML2 | KinaseFusionDB ID: KFG4662 | FusionGDB2.0 ID: KFG4662 | Hgene | Tgene | Gene symbol | PIM2 | STOML2 | Gene ID | 11040 | 30968 | |
Gene name | Pim-2 proto-oncogene, serine/threonine kinase | stomatin like 2 | ||||||||||
Synonyms | - | HSPC108|SLP-2 | ||||||||||
Cytomap | Xp11.23 | 9p13.3 | ||||||||||
Type of gene | protein-coding | protein-coding | ||||||||||
Description | serine/threonine-protein kinase pim-2pim-2 oncogenepim-2hproto-oncogene Pim-2 (serine threonine kinase) | stomatin-like protein 2, mitochondrialEPB72-like 2EPB72-like protein 2paraprotein target 7paratarg-7stomatin (EPB72)-like 2 | ||||||||||
Modification date | 20240407 | 20240407 | ||||||||||
UniProtAcc | Q9P1W9 | Q9UJZ1 | ||||||||||
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000376509, ENST00000485431, | ENST00000356493, ENST00000452248, ENST00000487490, | |||||||||
Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: PIM2 [Title/Abstract] AND STOML2 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | PIM2(48770524)-STOML2(35101012), # samples:1 STOML2(35101012)-PIM2(48770524), # samples:1 |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | PIM2 | GO:0000082 | G1/S transition of mitotic cell cycle | 20307683 |
Hgene | PIM2 | GO:0006468 | protein phosphorylation | 18593906 |
Hgene | PIM2 | GO:0008285 | negative regulation of cell population proliferation | 20307683 |
Hgene | PIM2 | GO:0043066 | negative regulation of apoptotic process | 18675992 |
Tgene | STOML2 | GO:0051259 | protein complex oligomerization | 17121834 |
Kinase Fusion gene breakpoints across PIM2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Kinase Fusion gene breakpoints across STOML2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
Kinase Fusion gene information. |
Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
ChiTaRS5.0 | BM693019 | PIM2 | chrX | 48770524 | STOML2 | chr9 | 35101012 |
Top |
Kinase Fusion ORF Analysis |
Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:48770524/:35101012) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
PIM2 | STOML2 |
FUNCTION: Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signaling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase transcriptional activity. The stabilization of MYC exerted by PIM2 might explain partly the strong synergism between these 2 oncogenes in tumorigenesis. Regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Promotes cell survival in response to a variety of proliferative signals via positive regulation of the I-kappa-B kinase/NF-kappa-B cascade; this process requires phosphorylation of MAP3K8/COT. Promotes growth factor-independent proliferation by phosphorylation of cell cycle factors such as CDKN1A and CDKN1B. Involved in the positive regulation of chondrocyte survival and autophagy in the epiphyseal growth plate. {ECO:0000269|PubMed:18593906, ECO:0000269|PubMed:18675992, ECO:0000269|PubMed:20307683}. | FUNCTION: Mitochondrial protein that probably regulates the biogenesis and the activity of mitochondria. Stimulates cardiolipin biosynthesis, binds cardiolipin-enriched membranes where it recruits and stabilizes some proteins including prohibitin and may therefore act in the organization of functional microdomains in mitochondrial membranes. Through regulation of the mitochondrial function may play a role into several biological processes including cell migration, cell proliferation, T-cell activation, calcium homeostasis and cellular response to stress. May play a role in calcium homeostasis through negative regulation of calcium efflux from mitochondria. Required for mitochondrial hyperfusion a pro-survival cellular response to stress which results in increased ATP production by mitochondria. May also regulate the organization of functional domains at the plasma membrane and play a role in T-cell activation through association with the T-cell receptor signaling complex and its regulation. {ECO:0000269|PubMed:17121834, ECO:0000269|PubMed:18641330, ECO:0000269|PubMed:19597348, ECO:0000269|PubMed:19944461, ECO:0000269|PubMed:21746876, ECO:0000269|PubMed:22623988}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of PIM2_STOML2 |
Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
PIM2 | Q9P1W9 | human | PKM | P14618 | T454 | RAPIIAVtRNPQtAR | PK_C |
PIM2 | Q9P1W9 | human | STAT5B | P51692 | S731 | TyMDQAPsPAVCPQA | |
PIM2 | Q9P1W9 | human | HK2 | P52789 | T473 | QHRARQktLEHLQLS | Hexokinase_1 |
PIM2 | Q9P1W9 | human | MYC | P01106 | S308 | GHskPPHsPLVLkrC | Myc_N |
PIM2 | Q9P1W9 | human | PFKFB3 | Q16875 | S478 | tKKPRINsFEEHVAS | |
PIM2 | Q9P1W9 | human | CDKN1A | P38936 | T145 | QGRkRRQtsMTDFyH | |
PIM2 | Q9P1W9 | human | LDHA | P00338 | S319 | EEARLkksADtLWGI | Ldh_1_C |
PIM2 | Q9P1W9 | human | LDHA | P00338 | S161 | PkNrVIGsGCNLDsA | |
PIM2 | Q9P1W9 | human | HSF1 | Q00613 | T120 | ENIkRkVtsVSTLks | |
PIM2 | Q9P1W9 | human | PRKAA1 | Q13131 | S467 | LQLyQVDsRTYLLDF | AdenylateSensor |
PIM2 | Q9P1W9 | human | CDKN1A | P38936 | S146 | GRkRRQtsMTDFyHs | |
PIM2 | Q9P1W9 | human | PSMD2 | Q13200 | S361 | ENNrFGGsGsQVDsA | |
PIM2 | Q9P1W9 | human | IRS1 | P35568 | S1101 | GCRRRHssEtFsStP | |
PIM2 | Q9P1W9 | human | FBP1 | P09467 | S144 | FGIYRKKsTDEPSEK | FBPase |
PIM2 | Q9P1W9 | human | PFKFB4 | Q16877 | T140 | TTRERRAtIFNFGEQ |
Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
Enriched GO biological processes of the phosphorylation target genes of the kinase |
Kinase | GOID | GO term | P.adjust |
PIM2 | ID | Description | 0.00e+00 |
PIM2 | GO:0019318 | hexose metabolic process | 5.66e-08 |
PIM2 | GO:0005996 | monosaccharide metabolic process | 6.28e-08 |
PIM2 | GO:0006096 | glycolytic process | 7.62e-07 |
PIM2 | GO:0006090 | pyruvate metabolic process | 2.39e-06 |
PIM2 | GO:0071375 | cellular response to peptide hormone stimulus | 4.87e-06 |
PIM2 | GO:0010332 | response to gamma radiation | 4.87e-06 |
PIM2 | GO:0016052 | carbohydrate catabolic process | 6.91e-06 |
PIM2 | GO:1901653 | cellular response to peptide | 9.04e-06 |
PIM2 | GO:0006000 | fructose metabolic process | 9.04e-06 |
PIM2 | GO:0006006 | glucose metabolic process | 1.12e-05 |
PIM2 | GO:0043434 | response to peptide hormone | 1.62e-05 |
PIM2 | GO:0046835 | carbohydrate phosphorylation | 3.29e-05 |
PIM2 | GO:0010212 | response to ionizing radiation | 1.26e-04 |
PIM2 | GO:0070482 | response to oxygen levels | 1.38e-04 |
PIM2 | GO:0071466 | cellular response to xenobiotic stimulus | 3.82e-04 |
PIM2 | GO:0009410 | response to xenobiotic stimulus | 3.82e-04 |
PIM2 | GO:0032869 | cellular response to insulin stimulus | 4.63e-04 |
PIM2 | GO:1901654 | response to ketone | 4.63e-04 |
PIM2 | GO:0006002 | fructose 6-phosphate metabolic process | 1.11e-03 |
PIM2 | GO:0032868 | response to insulin | 1.15e-03 |
PIM2 | GO:0001666 | response to hypoxia | 1.63e-03 |
PIM2 | GO:0036293 | response to decreased oxygen levels | 1.93e-03 |
PIM2 | GO:0071214 | cellular response to abiotic stimulus | 2.17e-03 |
PIM2 | GO:0104004 | cellular response to environmental stimulus | 2.17e-03 |
PIM2 | GO:0006735 | NADH regeneration | 2.17e-03 |
PIM2 | GO:0061621 | canonical glycolysis | 2.17e-03 |
PIM2 | GO:0061718 | glucose catabolic process to pyruvate | 2.17e-03 |
PIM2 | GO:0061620 | glycolytic process through glucose-6-phosphate | 2.60e-03 |
PIM2 | GO:0043467 | regulation of generation of precursor metabolites and energy | 3.21e-03 |
PIM2 | GO:0061615 | glycolytic process through fructose-6-phosphate | 3.51e-03 |
PIM2 | GO:0009411 | response to UV | 3.92e-03 |
PIM2 | GO:0006007 | glucose catabolic process | 4.06e-03 |
PIM2 | GO:0071480 | cellular response to gamma radiation | 4.06e-03 |
PIM2 | GO:0009314 | response to radiation | 4.10e-03 |
PIM2 | GO:0009266 | response to temperature stimulus | 4.91e-03 |
PIM2 | GO:0046685 | response to arsenic-containing substance | 5.24e-03 |
PIM2 | GO:0071478 | cellular response to radiation | 5.49e-03 |
PIM2 | GO:0006109 | regulation of carbohydrate metabolic process | 5.98e-03 |
PIM2 | GO:0031667 | response to nutrient levels | 6.18e-03 |
PIM2 | GO:0022411 | cellular component disassembly | 6.18e-03 |
PIM2 | GO:0071248 | cellular response to metal ion | 6.65e-03 |
PIM2 | GO:0046627 | negative regulation of insulin receptor signaling pathway | 7.29e-03 |
PIM2 | GO:0007595 | lactation | 7.29e-03 |
PIM2 | GO:1900077 | negative regulation of cellular response to insulin stimulus | 7.29e-03 |
PIM2 | GO:0045637 | regulation of myeloid cell differentiation | 7.29e-03 |
PIM2 | GO:0019320 | hexose catabolic process | 7.79e-03 |
PIM2 | GO:0071241 | cellular response to inorganic substance | 8.62e-03 |
PIM2 | GO:0006110 | regulation of glycolytic process | 1.02e-02 |
PIM2 | GO:0046365 | monosaccharide catabolic process | 1.02e-02 |
Top |
Related Drugs to PIM2_STOML2 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Distribution of the number of studies mentioning PIM2-STOML2 and kinase inhibitors the PubMed Abstract (04-01-2024) |
Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to PIM2_STOML2 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
MeSH ID | MeSH term |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
Clinical Trials from clinicaltrials.gov (06-17-2024) |
Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |